FMP
GlucoTrack, Inc.
GCTK
NASDAQ
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
0.352 USD
-0.0055 (-1.56%)
Operating Data
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue
208.76k
-
-
-
-
-
-
-
-
-
Revenue %
-
-100
-
-
-
-25
-25
-25
-25
Ebitda
-3.46M
-3.08M
-4M
-4.41M
-7.09M
-
-
-
-
-
Ebitda %
-1.65k
100
100
100
100
60
60
60
60
Ebit
-3.51M
-3.13M
-4.04M
-4.43M
-7.1M
-
-
-
-
-
Ebit %
-1.68k
100
100
100
100
60
60
60
60
Depreciation
51k
47k
42k
23k
13k
-
-
-
-
-
Depreciation %
24.43
100
100
100
100
84.89
84.89
84.89
84.89
Balance Sheet
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Total Cash
418.62k
9.82M
6.06M
2.31M
4.49M
-
-
-
-
-
Total Cash %
200.53
100
100
100
100
100
100
100
100
Receivables
70k
66k
-
-
-
-
-
-
-
-
Receivables %
33.53
100
100
100
100
86.71
86.71
86.71
86.71
Inventories
184.6k
284k
-
-
-
-
-
-
-
-
Inventories %
88.43
100
100
100
100
97.69
97.69
97.69
97.69
Payable
1.53M
869k
631k
672k
839k
-
-
-
-
-
Payable %
734.81
100
100
100
100
100
100
100
100
Cap Ex
-23.43k
-53k
-5k
-1k
-
-
-
-
-
-
Cap Ex %
-11.22
100
100
100
100
-2.24
-2.24
-2.24
-2.24
Weighted Average Cost Of Capital
Price
0.35
Beta
Diluted Shares Outstanding
4.15M
Costof Debt
4.09
Tax Rate
After Tax Cost Of Debt
4.09
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
196k
Total Equity
1.46M
Total Capital
1.66M
Debt Weighting
11.81
Equity Weighting
88.19
Wacc
4.92
Build Up Free Cash Flow
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue
208.76k
-
-
-
-
-
-
-
-
-
Ebitda
-3.46M
-3.08M
-4M
-4.41M
-7.09M
-
-
-
-
-
Ebit
-3.51M
-3.13M
-4.04M
-4.43M
-7.1M
-
-
-
-
-
Tax Rate
-
-
-
-
-
-
-
-
-
-
Ebiat
-3.51M
-3.02M
-4.07M
-4.43M
-7.1M
-
-
-
-
-
Depreciation
51k
47k
42k
23k
13k
-
-
-
-
-
Receivables
70k
66k
-
-
-
-
-
-
-
-
Inventories
184.6k
284k
-
-
-
-
-
-
-
-
Payable
1.53M
869k
631k
672k
839k
-
-
-
-
-
Cap Ex
-23.43k
-53k
-5k
-1k
-
-
-
-
-
-
Ufcf
-2.2M
-3.78M
-3.92M
-4.37M
-6.92M
-839k
-
-
-
-
Wacc
4.92
4.92
4.92
4.92
4.92
Pv Ufcf
-799.66k
0
0
0
0
Sum Pv Ufcf
-799.66k
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
4.92
Free Cash Flow T1
0
Terminal Value
0
Present Terminal Value
0
Intrinsic Value
Enterprise Value
-799.66k
Net Debt
-4.3M
Equity Value
3.5M
Diluted Shares Outstanding
4.15M
Equity Value Per Share
0.84
Projected DCF
0.84207 0.582%
